Company profile

Cycle Pharmaceuticals Ltd.

Privately held: no public share price (Cycle's official product and launch materials identify Cycle as the current commercial organization for Tascenso ODT and Bafiertam support after the Banner transition. Sources: https://www.bannerls.com/about ; https://cyclepharma.com/news/ms-patients-in-us-will-receive-equivalent-backing-from-cycle-pharmaceuticals-with-tascenso-odt/ Entity resolved by asset-pipeline-v2.)

Assets

(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Bafiertam(Bafiertam)
Approved
Nrf2 pathway (fumaric acid ester)Small molecule
Multiple Sclerosis
Tascenso ODT(Tascenso ODT)
Approved
S1P receptorSmall molecule
Multiple Sclerosis

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.